A. Wang

LBA34 Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC)

P. Galle, Ruifeng Xu, J. Llovet, 2022, Annals of Oncology.

LBA88 Belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC): Randomized open-label phase III LITESPARK-005 study

E. Verzoni, L. Albiges, D. Vickery, 2023, Annals of Oncology.